Move over Tolvaptan/Jynarque, there may be a new sheriff in town. On 05 June 2019 Texas-based Reata Pharmaceutical received orphan drug status from the FDA for Bardoxolone Methyl (aka Bardoxolone). So what does it mean if a drug is granted orphan status? It means that even though there are fewer than 200,000 people in the United States with the disease at any given time, the federal government has acknowledged the need for medical innovation to address the condition. Companies/drugs given this status receive certain development incentives such as tax credits for clinical testing, exemption from prescription drug user fees (used to fund new drug approval processes) and the ability to market the drug exclusively for seven years. I guess that takes the sting out of having a limited market. It may also explain why drugs such as Tolvaptan (also with orphan drug status) are so flippin' expensive! It's hard to recoup an investment when your upside is limited. So what's the...